Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model
- PMID: 113814
- DOI: 10.1007/BF00433561
Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model
Abstract
A hypothesis is briefly discussed proposing that schizophrenic symptoms are due to a breakdown in a mechanism by which conscious attention is limited and directed. It is shown that this mechanism can be modelled in terms of a simple nerve network in which every channel inhibits all the others. Failure of this inhibition would cause the defect hypothesised to occur in schizophrenia. It is shown that if dopamine is given a central role as transmitter in such a network then the various predictions about the biochemistry of schizophrenia that follow are not only consistent with the evidence for the 'dopamine theory' of schizophrenia, but also with much of the evidence held to be contrary to that theory. While not purporting to be an experimentally validated description of schizophrenia, this model goes beyond the single amine theories of schizophrenia and links dysfunctions in amine systems with specific behavioural control mechanisms. Given the current state of knowledge, such models can make only limited predictions about the biochemistry of schizophrenia. However, an attempt to link behavioural and biochemical systems in this way will be crucial for the development of viable animal models of schizophrenia.
Similar articles
-
A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges.Philos Trans R Soc Lond B Biol Sci. 1996 Oct 29;351(1346):1515-27. doi: 10.1098/rstb.1996.0138. Philos Trans R Soc Lond B Biol Sci. 1996. PMID: 8941963 Review.
-
A theory of dopamine function and its role in cognitive deficits in schizophrenia.Schizophr Bull. 1993;19(1):85-104. doi: 10.1093/schbul/19.1.85. Schizophr Bull. 1993. PMID: 8095737
-
Dopamine, cognitive control, and schizophrenia: the gating model.Prog Brain Res. 1999;121:327-49. doi: 10.1016/s0079-6123(08)63082-4. Prog Brain Res. 1999. PMID: 10551035 No abstract available.
-
Dopaminergic mechanisms in the pathogenesis of schizophrenia.FASEB J. 1992 Apr;6(7):2413-21. FASEB J. 1992. PMID: 1348713 Review.
-
Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia.Arch Gen Psychiatry. 1989 Aug;46(8):745-53. doi: 10.1001/archpsyc.1989.01810080075010. Arch Gen Psychiatry. 1989. PMID: 2665688 Review.
Cited by
-
Psychosis in Women: Time for Personalized Treatment.J Pers Med. 2021 Dec 2;11(12):1279. doi: 10.3390/jpm11121279. J Pers Med. 2021. PMID: 34945748 Free PMC article. Review.
-
Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.Psychopharmacology (Berl). 1994 Jun;115(1-2):185-95. doi: 10.1007/BF02244771. Psychopharmacology (Berl). 1994. PMID: 7862894
-
Role of monoamine pathways in attention and effort: effects of clonidine and methylphenidate in normal adult humans.Psychopharmacology (Berl). 1986;90(1):35-9. doi: 10.1007/BF00172868. Psychopharmacology (Berl). 1986. PMID: 3094059 Clinical Trial.
-
Altered spatial profile of distraction in people with schizophrenia.J Abnorm Psychol. 2017 Nov;126(8):1077-1086. doi: 10.1037/abn0000314. J Abnorm Psychol. 2017. PMID: 29154568 Free PMC article.
-
Neuroleptics and psychic indifference: a review.J R Soc Med. 1989 Oct;82(10):615-9. doi: 10.1177/014107688908201018. J R Soc Med. 1989. PMID: 2572700 Free PMC article. Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources